Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Dania Pagarkar joins Ethics Talk to discuss her article, coauthored with Drs Erin Harrop and Lisa Erlanger: “How Should We Approach Body Size Diversity in Clinical Trials?”
Dr Catherine V. Caldicott joins Ethics Talk to discuss why turfing, despite being such a common, troublesome ethical issue, receives such little attention in the literature, how clinicians can ensure appropriate and safe transfers of care, and what health professions students and trainees can do to confront turfing when they see it.
Dr Steven Starks joins Ethics Talk to discuss the shortage of geriatric psychiatrists and how cross-specialty training can prepare clinicians of all specialties to care for geriatric patients.